Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis.
High-density lipoproteins (HDL) are known to neutralize lipopolysaccharide (LPS). Because patients with cirrhosis have lower HDL levels, this may contribute to LPS-induced ex vivo monocyte overproduction of proinflammatory cytokines. However, the effects of HDL on cytokine production by monocytes from patients with cirrhosis have never been studied. The aim of this study was to determine the effects of HDL on LPS-induced proinflammatory cytokine production in whole blood and isolated monocytes from patients with severe cirrhosis and controls. Plasma levels of HDL and cytokines were determined. The effects of reconstituted HDL (rHDL) on LPS-induced cytokine production in whole blood were assessed by cytokine array and on tumor necrosis factor alpha (TNF-alpha) and interleukin-10 (IL-10) production in isolated monocytes. Plasma HDL levels were significantly lower in patients with cirrhosis than in controls. Plasma levels of TNF-alpha and IL-6 were significantly higher in patients with cirrhosis than in controls. Incubation of rHDL with whole blood prevented LPS-induced TNF-alpha and IL-6 overproduction in patients with cirrhosis. LPS-induced TNF-alpha production and CD14 expression were significantly more marked in cirrhotic monocytes than in control monocytes, and both decreased significantly after rHDL incubation. LPS-induced down-regulation of scavenger receptor, class B, type I (SR-BI) expression was abolished in cirrhotic monocytes.


CONCLUSIONS
This study shows that rHDL abolishes the LPS-induced overproduction of proinflammatory cytokines in whole blood from patients with severe cirrhosis. These results were confirmed in isolated monocytes from these patients. This suggests that administration of rHDL might be a useful strategy for the treatment of cirrhosis to limit LPS-induced cytokine overproduction.
Galbois
Arnaud
A
INSERM, U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Hôpital Beaujon, Clichy, France.
Thabut
Dominique
D
Tazi
Khalid A
KA
Rudler
Marika
M
Mohammadi
Morvarid Shir
MS
Bonnefont-Rousselot
Dominique
D
Bennani
Hind
H
Bezeaud
Annie
A
Tellier
Zera
Z
Guichard
Cécile
C
Coant
Nicolas
N
Ogier-Denis
Eric
E
Moreau
Richard
R
Lebrec
Didier
D
D000328:Adult; D002784:Cholesterol / Q000097:blood; D016207:Cytokines / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000139:chemically induced*; D016753:Interleukin-10 / Q000096:biosynthesis; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000494:pharmacology* / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism; D016328:NF-kappa B / Q000502:physiology; D051122:Scavenger Receptors, Class B / Q000096:biosynthesis; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D016207:Cytokines; D018950:Lipopolysaccharide Receptors; D008070:Lipopolysaccharides; D008075:Lipoproteins, HDL; D016328:NF-kappa B; C495124:SCARB1 protein, human; D051122:Scavenger Receptors, Class B; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D002784:Cholesterol